Clinical Trials
2 trialsNCT02917993 2026-02-09
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 1/2 Completed
NCT02646748 2022-03-31
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Incyte Corporation
Phase 1 Completed